{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Objectives', 'Enppoints', 'To evaluate the effect of GB001 on', 'Change from baseline to Week 16 in', 'maxillary CT opacification', 'percentage of maxillary sinus volume', 'occupied by disease on CT scan', 'To evaluate the effect of GB001 on', 'Proportion of subjects with antibiotic use due', 'worsening of CRS requiring the use', 'to worsening CRS by Week 16', 'of antibiotics', 'To evaluate pharmacokinetics (PK)', 'Plasma concentration of GB001', 'of GB001', 'To evaluate the effect of intervention', 'Correlation between baseline markers and', 'on, as a function of, the', 'safety, tolerability, and efficacy parameters', 'pharmacodynamic markers (PD)', 'Change in PD markers over time', 'To evaluate the relationship between', 'Correlation between baseline characteristics', 'safety, efficacy, and exposure', 'and single nucleotide polymorphisms', 'parameters and pharmacogenetics', 'Change from baseline in safety, efficacy,', '(PGx)', 'and exposure parameters as a function of', 'single nucleotide polymorphisms', '22', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '4.', 'STUDY DESIGN', '4.1.', 'Overall Design', 'This is a Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate', 'GB001 administered once a day for 16 weeks in subjects with chronic rhinosinusitis with or', 'without bilateral nasal polyps.', 'A schematic of the study design is presented in Section 1.2.', '4.1.1.', 'Study Design', 'Prior to screening, subjects must be on a stable regimen of intranasal corticosteroids (INCS) for', '> 2 months. If the subject is using an INCS product other than mometasone furoate nasal spray', '(MFNS) prior to the Screening visit, the Investigator must switch the subject to MFNS at the', 'Screening visit. All subjects will be maintained on a stable background therapy of mometasone', 'furoate nasal spray for the duration of the study.', 'Screening Visit (Visit 1): Informed consent will be obtained, and inclusion and exclusion', 'criteria will be assessed. Informed consent may be obtained prior to the day of the Screening', 'visit to allow for medication washouts or for other logistical reasons such as obtaining', 'documentation of exacerbations, if necessary. All other screening procedures should be', 'completed, where possible, on the day of the Screening visit. Subjects not meeting the eligibility', 'criteria will be deemed screen failures and will not continue participation in the study (see', 'Section 5.4). The Run-in period commences with completion of all Screening visit procedures', 'and concludes at the Randomization visit (Visit 2). During the Run-in period of up to 4 weeks,', 'subjects will capture nasal symptoms and MFNS use in a Diary daily (morning and evening):', \"Subject's treatment regimen with MFNS should remain stable.\", '2 actuations (50 g/actuation) in each nostril twice daily (total daily dose of 400 g),', 'unless subject is intolerant to a twice daily (BID) regimen of MFNS in which case,', 'they can stay on the dose regimen in place prior to screening.', 'The only dose modification of MFNS during the Run-in period may be for subjects', 'who were switched from another INCS to MFNS and need to change to a QD', 'regimen due to intolerability.', 'Randomization Visit (Day 1/Week 0/Visit 2): Subjects who meet the randomization eligibility', 'criteria will be randomized in a 1:1 ratio to receive one of the following double-blind treatments', 'for 16 weeks:', 'GB001 40 mg once per day (QD)', 'Matching placebo once per day (QD)', 'Randomization will be stratified by country, the presence or absence of NP (CRSwNP and', 'CRSsNP), and the presence or absence of comorbid asthma among CRSwNP subjects. Presence', 'of NP is defined by a minimum NPS of 4 out of a maximum score of 8 with a score of at least 2', 'for each nostril. Absence of NP is defined as an absence of NP based on visual examination or an', 'NPS of 0 based on nasal endoscopy. Presence of comorbid asthma is defined as a diagnosis of', 'asthma by a physician according to Global Initiative for Asthma (GINA) guidelines at screening', '23', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'or prior to study entry. The CRSwNP stratum will consist of approximately 64 subjects, and the', 'CRSsNP stratum will consist of approximately 36 subjects.', 'Subjects will continue on mometasone furoate: MFNS two actuations in each nostril BID (or QD', 'in case subject cannot tolerate the high dose) during the course of the study.', 'Following initiation of investigational product (IP) at the clinic, subjects will visit the clinic', 'weekly for the first 6 weeks and approximately every 4 weeks thereafter through week 20, for a', 'total of 10 additional visits (refer to Schedule of Activities, Section 1.3).', 'Early Discontinuation of IP and Early Withdrawal from Study: Subjects will be requested to', 'attend the Early Discontinuation of IP or Early Withdrawal (EW) visit, as appropriate, and will', 'be strongly encouraged to complete any remaining study visits as per the Schedule of Activities', '(SoA; Section 1.3). Subjects who permanently discontinue IP and continue in the study will', 'complete the Early Discontinuation of IP visit at the time of IP discontinuation and then return', 'for the next visit in the visit sequence. At the visits after the Early Discontinuation of IP visit,', 'study procedures will be completed except for dispensation/return of IP. Subjects who withdraw', 'early from the study, regardless of the reason, will be requested to return to the clinic to complete', 'the EW visit. All subjects who remain on IP through and including Visit 7 (Week 16) or who', 'complete the EW visit will be asked to return for a Follow-up visit approximately 4 weeks after', 'their last dose of IP to assess subject safety.', 'Follow-up Period: Subjects can continue treatment with the stable dose of MFNS maintained', 'over the Double-Blind, Placebo-Controlled period, or modify treatment based on medical', 'judgment.', 'Total duration for study participation per subject is up to 24 weeks (includes a Screening visit,', 'followed by an up to 4-weeks Run-in period to allow for collection of baseline Diary data;', 'a 16-week Double-Blind, Placebo-Controlled period; and 4-week Follow-up period).', '4.1.2.', 'Unscheduled Visit', 'There may be a need to have a subject return to clinic for an unscheduled visit for a variety of', 'reasons, including but not limited to: repeat of a lab test, replacement of IP, or evaluation of an', 'AE. Any procedure that is conducted during a regularly scheduled on-treatment visit may be', 'performed at an unscheduled visit.', '4.2.', 'Scientific Rationale for Study Design', '4.2.1.', 'Study Population', 'The study population is comprised of: symptomatic CRS subjects with CRSsNP, defined as an', 'absence of NP based on visual examination or an NPS of 0 based on nasal endoscopy, and', 'evidence of an eosinophilic phenotype (eCRS), defined as a blood eosinophil count of > 250', 'cells/uL; and symptomatic CRS subjects with CRSwNP, defined as a minimum NPS of 4 out of', 'a maximum of 8, with at least a score of 2 for each nostril, as assessed by endoscopic diagnosis', 'by a blinded central reader. Subjects with historical evidence of neutrophilic predominant polyp', 'disease will be excluded considering that the mechanism of action of GB001 is thought to be', 'linked to eosinophilic Type 2 inflammation. The overall study population will consist of', 'approximately 64 CRSwNP subjects and 36 CRSsNP subjects.', '24', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}